comprehensive -WSS

comprehensive

author：comprehensive 2025-08-12 08:30:04 - browse：837

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Lung cancer screening guidelines updated for cigarette smokers

WSS

How neuroscience research could help beat back brain cancer

After Sarepta trial failure, Duchenne families brace for more debate

Congress considering partial increase for doctor pay in Medicare

Too many hospitalized Covid

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Sarepta Duchenne therapy fails to meet primary endpoint in trial

entertainment

comprehensive

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

After Sarepta trial failure, Duchenne families brace for more debate

DIEP, the 'gold standard' of breast reconstruction, is under threat

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

How one medical school became remarkably diverse

Congress might make insulin pumps more accessible to the blind

State Dept. review finds Biden bears some blame for Afghanistan failures

Inari Medical to buy amputation prevention company LimFlow

leisure time

Readout LOUD podcast: ESMO highlights & Roivant's big deal

AMAs digital advisors table RPM coding reform proposal, again

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Medicare proceeds with plan to claw back hospital funds

Congress must protect the remaining independent doctors

Sarepta Duchenne therapy fails to meet primary endpoint in trial

leisure time

entertainment

hotspot

explore